0001209191-21-014007.txt : 20210224 0001209191-21-014007.hdr.sgml : 20210224 20210224194504 ACCESSION NUMBER: 0001209191-21-014007 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210224 FILED AS OF DATE: 20210224 DATE AS OF CHANGE: 20210224 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pomerantz Roger CENTRAL INDEX KEY: 0001614936 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 21675792 MAIL ADDRESS: STREET 1: 711 HARVEST HILL ROAD CITY: CHALFONT STATE: PA ZIP: 18914 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUNESIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 395 OYSTER POINT BOULEVARD STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-3500 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BOULEVARD STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-02-24 0 0001061027 SUNESIS PHARMACEUTICALS INC VIRX 0001614936 Pomerantz Roger C/O VIRACTA THERAPEUTICS, INC. 2533 S COAST HWY 101, SUITE 210 CARDIFF CA 92007 1 0 0 0 Restricted Stock Units 0.00 Common Stock 144547 D Stock Option (Right to Buy) 1.26 2030-07-27 Common Stock 65379 D Stock Option (Right to Buy) 1.26 2030-09-13 Common Stock 65379 D Stock Option (Right to Buy) 3.58 2031-01-08 Common Stock 72240 D One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of July 27, 2020 (the "Vesting Commencement Date"), and one forty-eighth (1/48th ) of the total shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Plan) through each such date. Notwithstanding the foregoing and anything to the contrary in the Plan, in the event a Change in Control (as such term is defined in the Plan) of the Company occurs while reporting person is a Service Provider of the Company, one hundred percent (100%) of the unvested shares subject to the Option shall vest and become immediately exercisable. Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of September 13, 2020 (the "Vesting Commencement Date"), and one forty-eighth (1/48th ) of the total shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Plan) through each such date. Notwithstanding the foregoing and anything to the contrary in the Plan, in the event a Change in Control (as such term is defined in the Plan) of the Company occurs while reporting person is a Service Provider of the Company, one hundred percent (100%) of the unvested shares subject to the Option shall vest and become immediately exercisable. One forty-eighth (1/48th ) of the Shares subject to the Option shall vest on February 28, 2021, and one forty-eighth (1/48th ) of the total Shares subject to the Option shall vest each month thereafter on the last day of such month, subject to the reporting person continuing to be a Service Provider (as defined in the Company's 2016 Equity Incentive Plan) through each such date. Exhibit 24: Power of Attorney /s/ Michael Mueller, as Attorney-in-Fact 2021-02-24 EX-24 2 attachment1.htm EX-24 DOCUMENT

Exhibit 24

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Viracta Therapeutics, Inc.
(the "Company"), hereby constitutes and appoints Ivor Royston, Daniel
Chevallard, Michael Mueller, Shelly Vandertie, Ben Capps, and Brandon Shaw the
undersigneds true and lawful attorneys-in-fact to:

1.	complete and execute Forms 3, 4 and 5 and other forms and all amendments
thereto as such attorneys-in-fact shall in their discretion determine to be
required or advisable pursuant to Section 16 of the Securities Exchange Act of
1934 (as amended) and the rules and regulations promulgated thereunder, or any
successor laws and regulations, as a consequence of the undersigneds ownership,
acquisition or disposition of securities of the Company; and

2.	do all acts necessary in order to file such forms with the Securities and
Exchange Commission, any securities exchange or national association, the
Company and such other person or agency as the attorneys-in-fact shall deem
appropriate.

The undersigned hereby ratifies and confirms all that said attorneys in-fact and
agent shall do or cause to be done by virtue hereof.  The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, is not assuming, nor is the Company assuming,
any of the undersigneds responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigneds holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 24th day of February, 2021.



Signature:  /s/ Roger Pomerantz

Print Name:   Roger Pomerantz